News summary produced by Claude AI
A remote town in southern Ecuador called Piñas has an unusually high concentration of people with Laron syndrome, a rare genetic disorder that limits human growth to approximately 1.2 meters. Twin sisters María Luísa Romero and María del Cisne both have the condition and have become central to ongoing medical research examining potential health benefits associated with the syndrome.
Researchers, including endocrinologist Dr. Jaime Guevara and aging specialist Dr. Valter Longo, have identified that individuals with Laron syndrome show significantly lower rates of cancer and diabetes compared to the general population. Over a 22-year study involving approximately 100 people with Laron syndrome and 1,600 relatives of typical height living in the same villages, researchers found no diabetes cases among Laron patients and only one non-fatal cancer case, while 5% of those with normal height developed diabetes and 17% developed cancer. The condition is caused by a genetic mutation affecting the growth hormone receptor, preventing the body from producing sufficient levels of Insulin-like Growth Factor 1 (IGF-1).
Scientists theorize that lower IGF-1 levels in Laron patients may prevent cancer cells from undergoing apoptosis, or programmed cell death. Researchers hope to replicate these protective mechanisms through pharmaceutical or dietary interventions for people without the syndrome. A comprehensive research paper documenting all known cases of Laron syndrome identified between 1966 and 2025 is scheduled for publication later in July.
However, the protective effects are not absolute. María del Cisne was diagnosed with colon cancer two years ago, requiring surgery and chemotherapy, prompting both sisters to reassess their understanding of the condition’s protective qualities. Despite these challenges, both twins view their participation in research as meaningful. For those born with Laron syndrome, a drug called Increlex can increase height during childhood, though access remains limited due to high costs and production constraints. The twins, now 40 years old, missed the treatment window during their childhood years.